🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity · Phase III

Metabolic & obesity programs at Phase III — ClinicalTrials.gov pipeline intelligence.

Programs
227

Quick answer

Metabolic & obesity Phase III programs: NovaPharmaNews indexes 227 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 2 of 5

  1. Eloralintide, Eloralintide, Eloralintide, Placebo to match LY, Eloralintide

    Eli Lilly Co.

    Overweight, Obesity, Sleep Apnea, Obstructive

    phase 3 small molecule active

    1 trial

  2. Eloralintide, Eloralintide, Placebo to match LY, Eloralintide, Eloralintide

    Eli Lilly Co.

    Overweight, Obesity

    phase 3 small molecule active

    1 trial

  3. Eloralintide, Placebo to match LY, Eloralintide, Eloralintide, Eloralintide

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  4. Empagliflozin 10 MG

    Hospital Authority, Hong Kong

    Diabetic Nephropathies

    phase 3 small molecule terminated

    1 trial

  5. Empagliflozin 20 mg

    COLLEGIUM PHARMACEUTICAL, INC

    Metabolic Syndrome

    phase 3 small molecule active

    1 trial

  6. Faricimab

    Hoffmann-La Roche

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  7. Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes

    Lxo Ireland Designated Activity Company

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  8. Fasiglifam (TAK-875)

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule terminated

    1 trial

  9. Faster-acting insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial

  10. Finerenone (BAY94-8862)

    Bayer HealthCare AG

    Diabetic Kidney Disease

    phase 3 small molecule completed

    1 trial

  11. Finerenone, Placebo, Placebo, BAY 94-8862

    Bayer AG

    Non-diabetic chronic kidney disease

    phase 3 small molecule active

    1 trial

  12. Glargine

    Eli Lilly and Company

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  13. Glimepiride

    Janssen Cilag International NV

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  14. Glucagon

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 3 small molecule completed

    1 trial

  15. HS-20094 Injection

    Jian Li

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  16. Human Insulin Inhalation Powder

    Eli Lilly and Company

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  17. Identical to kai-9531 solution for injection without active drug, KAI-9531, KAI-9531, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  18. Inhaled Human Insulin

    Nektar Therapeutics UK Limited

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  19. Insulin Degludec and Insulin Aspart

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Diabetes

    phase 3 small molecule completed

    1 trial

  20. Insulin degludec/insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial

  21. Insulin glargine/Lixisenatide (HOE901/AVE0010)

    Sanofi Pasteur

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  22. Insulin icodec

    Novo Nordisk A/S

    Diabetes, Type 2

    phase 3 small molecule completed

    1 trial

  23. Intravitreal Aflibercept Injection (IAI)

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  24. Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  25. Intravitreal aflibercept injection [IAI]

    Regeneron UK Limited

    Nonproliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  26. Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat, BI 690517

    Boehringer Ingelheim

    Type 2 diabetes, hypertension, cardiovascular disease

    phase 3 small molecule active

    1 trial

  27. KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    3 trials

  28. KAI-9531

    Kailera Therapeutics

    Obesity With Diabetes

    phase 3 small molecule active

    1 trial

  29. KAI-9531, KAI-9531, Identical to kai-9531 solution for injection without active drug, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  30. Khalas dates

    United Therapeutics Europe Ltd

    Diabetes Mellitus

    phase 3 other completed

    1 trial

  31. LMF237 50/250 mg

    Novartis Pharmaceuticals

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  32. LY2189265

    United Therapeutics Europe Ltd

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  33. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen

    NovoThirteen

    Type 1 Diabetes

    phase 3 small molecule active

    1 trial

  34. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, insulin icodec 700 U/mL PDS290

    NovoThirteen

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  35. Lapaquistat acetate and lipid-lowering therapy

    Takeda

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  36. Lifestyle modification

    Takeda

    Type 2 Diabetes

    phase 3 other completed

    1 trial

  37. Linagliptin

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    3 trials

  38. Liraglutide placebo, Saxenda 6 mg/mL solution for injection in pre-filled pen

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  39. METFORMIN

    Pari Pharma GmbH

    Type 2 Diabetes complete remission after bariatric surgery under antidiabetic drug

    phase 3 small molecule active

    1 trial

  40. METFORMIN , DAPAGLIFLOZIN

    Eli Lilly Co.

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  41. METFORMINE ARROW LAB 1000 mg, comprimé pelliculé sécable, Placebo de metformine Arrow Lab 1000 mg - Composition: Cellulose microcristalline; Lactose monohydraté; Stéarate de magnésium (vegetable origin); Opadry TM 07F28588; Eau purifiée

    Pari Pharma GmbH

    Vascular calcification and type 1 diabetes

    phase 3 small molecule active

    1 trial

  42. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    NASH - Nonalcoholic Steatohepatitis

    phase 3 small molecule active

    1 trial

  43. MGL-3196 80 mg oral, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 60 mg film-coated tablet, MGL-3196 60 mg oral, MGL-3196 100 mg oral, Matching placebo MGL-3196 100 mg film-coated tablet

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis (NASH) Cirrhosis

    phase 3 small molecule active

    1 trial

  44. Maridebart cafraglutide

    Amgen

    Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

    phase 3 small molecule active

    1 trial

  45. Matching placebo MGL-3196 60 mg film-coated tablet, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 100 mg film-coated tablet., MGL-3196 60 mg oral, MGL-3196 100 mg oral, MGL-3196 80 mg oral

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  46. Metformin

    AstraZeneca

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  47. Metformin on top of intensive insulin therapy

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  48. Metformin plus pioglitazone

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many metabolic & obesity Phase III programs exist?

227 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.